Kura Oncology, Inc. (Kura)

Oncology Corporate Profile

HQ Location

11119 North Torrey Pines Road, Suite 125
La Jolla, CA 92037

Company Description

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura Oncology's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines.

Website: http://www.kuraoncology.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tipifarnibfarnesyl transferase inhibitorsChronic Myelomonocytic LeukemiaII
tipifarnibfarnesyl transferase inhibitorsMyelodysplastic Syndrome (MDS)II
tipifarnibfarnesyl transferase inhibitorsT-cell LymphomaII
tipifarnibfarnesyl transferase inhibitorsVarious cancer typesII
KO-947ERK inhibitorVarious cancer typesI
KO-539menin MLL inhibitorLeukemiaPreclinical

View additional information on product candidates here »

Source: http://www.kuraoncology.com/

Recent News Headlines

6/26/2017 06:18 am

6/26/2017 06:18 am

6/26/2017 06:18 am

6/14/2017 06:18 am

6/14/2017 06:18 am

6/14/2017 06:18 am

6/12/2017 12:18 pm

6/7/2017 06:18 am

6/7/2017 06:18 am

6/5/2017 12:19 pm

5/30/2017 06:18 am

5/30/2017 06:18 am

5/30/2017 06:18 am

5/28/2017 06:18 am

5/15/2017 12:18 pm

5/10/2017 12:18 pm

5/8/2017 12:18 pm

4/19/2017 06:18 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017

3/29/2017 11:03 am

[GlobeNewswire] - LA JOLLA, Calif., March 29, 2017-- Kura Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines, today announced that results from preclinical studies ...